Table S1 (DOC) References H3N2 viruses neutralized by PN-SIA28. Data from two different experiments for each strain are reported. Each point was performed in triplicate. (TIF) Figure S3 Unrooted tree of HA1 region of H3 hemag- glutinins. The different isolates belong to different historical periods spanning 1968 to 2009. The three different clusters characterizing the H3N2 pandemic are evidenced, with each cluster including isolates belonging to a distinct time period of the pandemic. Green ‘+’ or red ‘2’ indicate PN-SIA28 positive and negative neutralizing activity, respectively. (TIF) HA amino acidic residues mutated in H1 and H3. 1. Morens DM, Taubenberger JK, Folkers GK, Fauci AS (2010) Pandemic influenza’s 500th anniversary. Clin Infect Dis 51: 1442–1444. 2. Taubenberger JK, Morens DM (2010) Influenza: the once and future pandemic. Public Health Rep 125 Suppl 3: 16–26. 3. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, et al. (2007) The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25: 5086–5096. 4. Xue Y, Kristiansen IS, de Blasio BF (2010) Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave. BMC Public Health 10: 724. 5. Cheng PK, Leung TW, Ho EC, Leung PC, Ng AY, et al. (2009) Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis 15: 966–968. 6. Ramirez-Gonzalez JE, Gonzalez-Duran E, Alcantara-Perez P, Wong- Arambula C, Olivera-Diaz H, et al. (2011) Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, Mexico. Emerg Infect Dis 17: 283–286. 7. Beigel J, Bray M (2008) Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 78: 91–102. 8. Burioni R, Canducci F, Clementi M (2009) Pregnancy and H1N1 infection. Lancet 374: 1417; author reply 1417–1418. 9. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H (2009) Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey. Euro Surveill 14: 19287. 10. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montano LF, et al. (2009) Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 27: 5043–5053. 11. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143–155. 12. Nabel GJ, Fauci AS (2010) Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 16: 1389–1391. 13. Ansaldi F, Canepa P, Parodi V, Bacilieri S, Orsi A, et al. (2009) Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 27: 3345–3348. 14. Lambert LC, Fauci AS (2010) Influenza vaccines for the future. N Engl J Med 363: 2036–2044. 15. Stanekova Z, Vareckova E (2010) Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 7: 351. 16. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, et al. (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1: doi: 10.1128/mBio.00018-10. 17. Gamblin SJ, Skehel JJ (2010) Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285: 28403–28409. 18. Carrat F, Flahault A (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25: 6852–6862. 19. Burioni R, Canducci F, Mancini N, Clementi N, Sassi M, et al. (2010) Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology 399: 144–152. 20. Burioni R, Canducci F, Mancini N, Clementi N, Sassi M, et al. (2009) Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiol 32: 319–324. 21. Lamarre A, Talbot PJ (1995) Protection from lethal coronavirus infection by immunoglobulin fragments. Journal of immunology 154: 3975–3984. 22. Ma JK, Hunjan M, Smith R, Kelly C, Lehner T (1990) An investigation into the mechanism of protection by local passive immunization with monoclonal Cross-Neutralizing mAb to Influenza Viruses Acknowledgments We would like to thank Matteo Castelli and Vittoria Gagnoni Schippisi for their technical support. Author Contributions Conceived and designed the experiments: NC DDM NM LS LVG VM MC RB. Performed the experiments: NC DDM GJM VM ADP. Analyzed the data: NC DDM NM LS LVG VM ADP EV AGS. Contributed reagents/materials/analysis tools: LVG EV MC RB. Wrote the paper: NC DDM NM LS RB. antibodies against Streptococcus mutans. Infection and immunity 58: 3407–3414. 23. Yoden S, Kida H, Yanagawa R (1985) Is bivalent binding of monoclonal antibodies to different antigenic areas on the hemagglutinin of influenza virus required for neutralization of viral infectivity? Archives of virology 85: 209–216. 24. Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, et al. (2004) Identification and characterization of a new cross-reactive human immunode- ficiency virus type 1-neutralizing human monoclonal antibody. Journal of virology 78: 9233–9242. 25. Corti D, Suguitan AL, Jr., Pinna D, Silacci C, Fernandez-Rodriguez BM, et al. (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120: 1663–1673. 26. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246–251. 27. Kashyap AK, Steel J, Rubrum A, Estelles A, Briante R, et al. (2010) Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog 6: e1000990. 28. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265–273. 29. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+memory B cells. PLoS One 3: e3942. 30. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, et al. (2011) A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses. Science 333(6044): 843–850. doi: 10.1126/science.1204839. 31. Wang TT, Tan GS, Hai R, Pica N, Petersen E, et al. (2010) Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 6: e1000796. 32. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850–856. 33. Burioni R, Perotti M, Mancini N, Clementi M (2008) Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J Hepatol 49: 299–300. 34. Clementi M, Burioni R (2007) Is reduction of viral fitness a valid antiviral approach? Drug Discov Today: Therapeutic Strategies 4: 267–272. 35. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10: 301–316. 36. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clinical pharmaco- kinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49: 493–507. 37. Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, et al. (2010) New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 5: e9106. 38. Koudstaal W, Koldijk MH, Brakenhoff JP, Cornelissen LA, Weverling GJ, et al. (2009) Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir. J Infect Dis 200: 1870–1873. 39. Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le MQ, et al. (2010) A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res 88: 249–255. 40. Burioni R, Mancini N, De Marco D, Clementi N, Perotti M, et al. (2008) Anti- HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS One 3: e3423. 41. Okuno Y, Isegawa Y, Sasao F, Ueda S (1993) A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67: 2552–2558. PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28001